Intensity Therapeutics Receives Fast Track Designation from U.S. FDA for Development of INT230-6 as Treatment for Relapsed or Metastatic Triple Negative Breast Cancer

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability